US EditionCambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts
- Cambrex announced the expansion of Snapdragon Chemistry's active pharmaceutical ingredient facility in Waltham, Massachusetts, to support peptide therapy manufacturing.
- The new GMP manufacturing suite increases the facility size by 20% and features an ISO-7 cleanroom and cold storage.
- Snapdragon can now support peptide projects from development to GMP manufacturing using various synthesis methods.
- Cambrex is investing in R&D for complex synthetic modalities and innovations in peptide manufacturing.
74 Articles
74 Articles
Chatham Star Tribune
Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts
EAST RUTHERFORD, N.J., Aug. 25, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts to further support…
Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its Active Pharmaceutical Ingredients (API) facility in Waltham, Massachusetts to further support the development and production of peptide therapies.
Open the article to view the coverage from TOP News Austria - News from Austria and the whole world
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
